Area of research
Physiology · Neurology
Research interest
Research interests include Alzheimer's disease research and treatments, Amyotrophic Lateral Sclerosis Research, Parkinson's Disease Mechanisms and Treatments, and Cellular transport and secretion.
GRAMD1B is a regulator of lipid homeostasis, autophagic flux and phosphorylated tau
Second international symposium on the chaperone code, 2023
Mutations in α-synuclein, TDP-43 and tau prolong protein half-life through diminished degradation by lysosomal proteases
Tau Post-translational Modifications: Dynamic Transformers of Tau Function, Degradation, and Aggregation
Genetically Encoded, pH-Sensitive mTFP1 Biosensor for Probing Lysosomal pH
Processing of progranulin into granulins involves multiple lysosomal proteases and is affected in frontotemporal lobar degeneration
TSC1 loss increases risk for tauopathy by inducing tau acetylation and preventing tau clearance via chaperone-mediated autophagy
A Comprehensive Resource for Induced Pluripotent Stem Cells from Patients with Primary Tauopathies
Progranulin Stimulates the In Vitro Maturation of Pro-Cathepsin D at Acidic pH
Age- and stress-associated C. elegans granulins impair lysosomal function and induce a compensatory HLH-30/TFEB transcriptional response
Clinicopathological correlations in behavioural variant frontotemporal dementia
Progranulin, lysosomal regulation and neurodegenerative disease
MCP‐1 and eotaxin‐1 selectively and negatively associate with memory in MCI and Alzheimer's disease dementia phenotypes
The Progranulin Cleavage Products, Granulins, Exacerbate TDP-43 Toxicity and Increase TDP-43 Levels
Whole-genome sequencing suggests a chemokine gene cluster that modifies age at onset in familial Alzheimer's disease
Frontotemporal degeneration, the next therapeutic frontier: Molecules and animal models for frontotemporal degeneration drug development
The advantages of frontotemporal degeneration drug development (part 2 of frontotemporal degeneration: The next therapeutic frontier)